Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Launched by INSTITUT BERGONIÉ · Aug 25, 2015

Keywords

ClinConnect Summary

The Bergonie Institut Profiling trial is a study aimed at finding specific changes in the genes of cancer cells in patients who have advanced solid tumors or blood cancers. By using advanced techniques like next-generation sequencing, which looks at the DNA of the cancer, and immunological profiling, the researchers hope to identify unique features of each patient’s cancer. If a patient has a genetic change that can be targeted with a treatment, they may have the opportunity to participate in early-stage clinical trials at the Institut Bergonie or another hospital in France.

To be eligible for this study, patients must be at least 18 years old and diagnosed with either a solid tumor or a blood cancer. They also need to have a social security number in line with French regulations and must provide written consent to participate. The trial is currently looking for participants, and it is open to individuals of any gender. Those who join can expect to undergo testing that will help identify potential treatment options tailored to their specific cancer profile, which could lead to new and effective therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years,
• • 2. Histology: solid malignant tumor or hematological malignancy,
• • 3. Deleted MSA9
• • 4. Deleted MSA9,
• • 5. Deleted MSA9,
• • 6. Deleted MSA9,
• • 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code),
• • 8. Voluntary signed and dated written informed consent prior to any study specific procedure.
• Exclusion Criteria:
• • 1. Deleted MSA9
• • 2. Deleted MSA9
• • 3. Deleted MSA9
• • 4. Deleted MSA9
• • 5. Deleted MSA9
• • 6. Deleted MSA9
• • 7. Deleted MSA9
• • 8. Deleted MSA9
• • 9. Individuals deprived of liberty or placed under guardianship
• • 10. Pregnant or breast feeding women,
• • 11. Previous enrolment in the present study.